FDA Approves Moderna mFLUSIVA, the First mRNA Seasonal Flu Vaccine in the U.S.

By AiCybr Editorial · Published August 8, 2026

The U.S. Food and Drug Administration has approved Moderna’s mFLUSIVA (mRNA-1010) for adults aged 50 and older, making it the first seasonal influenza vaccine approved in the United States that uses messenger RNA technology.

The approval is not identical across all eligible adults. People aged 50 through 64 received traditional approval, while adults 65 and older received accelerated approval, which requires additional confirmatory evidence.

The headline clinical result also needs careful interpretation: in Moderna’s pivotal Phase 3 study, mRNA-1010 showed 26.6% relative vaccine efficacy compared with a licensed standard-dose flu vaccine. That does not mean the shot provides 26.6% absolute protection against influenza, nor does it establish an 83% absolute efficacy rate.

mFLUSIVA approval at a glance

What the 26.6% efficacy number actually means

The most important number in the trial is easy to misread.

The Phase 3 Fluent trial compared mRNA-1010 with an already licensed standard-dose influenza vaccine, not a placebo. Among participants included in the per-protocol efficacy analysis, RT-PCR-confirmed protocol-defined influenza-like illness occurred in:

• 411 of 20,179 mRNA-1010 recipients (2.0%)
• 557 of 20,124 standard-dose-vaccine recipients (2.8%)

That produced a relative vaccine efficacy (rVE) of 26.6%, with a 95% confidence interval of 16.7% to 35.4%.

In other words, the trial measured the additional reduction in influenza risk from mRNA-1010 relative to another active flu vaccine. The FDA’s own presentation explicitly states that this is not an estimate of absolute vaccine efficacy because the study did not compare mRNA-1010 with placebo.

The trial’s prespecified statistical hierarchy tested noninferiority, superiority and a stricter level of superiority. The result met all three criteria.

This distinction matters because describing the result simply as “26.6% effective” understates what was measured, while converting it into an unsupported absolute efficacy percentage overstates what the trial established.

The Phase 3 trial was large and peer reviewed

The pivotal P304 study was a randomized, double-blind, active-controlled Phase 3 trial conducted across the 2024–2025 influenza season. The published New England Journal of Medicine analysis included 40,703 vaccinated adults aged 50 or older, split almost evenly between mRNA-1010 and a licensed standard-dose comparator.

Participants were followed for a median of 181 days for the efficacy analysis. Influenza cases had to meet the protocol’s illness definition and be confirmed by RT-PCR.

The trial used a trivalent version of mRNA-1010 at a total dose of 37.5 micrograms, comprising 12.5 micrograms for each of three influenza strains.

The study therefore provides substantially stronger evidence than an early-stage immunogenicity trial or a company-only benchmark. Its central efficacy result has been published in a peer-reviewed medical journal and was independently scrutinized in FDA advisory materials.

Why the approval pathway changes at age 65

The FDA considered two distinct regulatory questions.

For adults 50 through 64, the agency evaluated whether the P304 clinical efficacy data were sufficient for traditional approval.

For adults 65 and older, the FDA evaluated an accelerated-approval pathway based partly on comparative immune-response data against a high-dose influenza vaccine, which is among the vaccine types preferentially recommended for older adults because immune responses generally weaken with age.

Moderna’s separate Phase 3 Study P303 Part C enrolled 2,992 adults aged 65 or older and compared immune responses with a high-dose influenza vaccine. FDA briefing documents describe this evidence as part of the basis for accelerated approval in the older population, together with a required Phase 4 confirmatory study.

Accelerated approval therefore should not be read as identical to the traditional approval granted for ages 50–64. It allows use based on the evidence package accepted by the FDA while requiring the manufacturer to confirm the anticipated clinical benefit after approval.

How mFLUSIVA works

mFLUSIVA uses the same broad platform concept that made mRNA widely known during the COVID-19 pandemic, but the encoded target is different.

The vaccine packages messenger RNA inside lipid nanoparticles (LNPs). The mRNA instructs cells to temporarily produce influenza hemagglutinin (HA) antigens, which the immune system can recognize and respond to.

According to FDA briefing documents, the trivalent formulation encodes HA glycoproteins corresponding to:

• influenza A/H1N1
• influenza A/H3N2
• influenza B/Victoria

The mRNA itself does not need to contain live influenza virus, and manufacturing does not require propagating the vaccine virus in chicken eggs.

Why mRNA is interesting for seasonal influenza

Seasonal influenza presents a manufacturing problem that differs from many other vaccine targets: the formulation is updated repeatedly as circulating strains evolve.

Traditional egg-based manufacturing remains widely used, but growing influenza viruses in eggs can introduce egg-adaptive mutations. FDA briefing materials note that these changes can alter antigen conformation and contribute to mismatch between the manufactured vaccine strain and circulating viruses.

An mRNA platform avoids that virus-propagation step. It can also shorten parts of the manufacturing process because manufacturers can synthesize a new RNA sequence after strains are selected rather than first adapting and amplifying a vaccine virus in eggs.

That gives mRNA technology a potentially important engineering advantage: later strain selection and faster formulation updates may reduce some sources of mismatch.

It does not guarantee that every mRNA flu vaccine will outperform every conventional vaccine. Influenza effectiveness still depends on which strains circulate, how those strains evolve, population immunity, age, the comparator vaccine and the specific season being studied.

The trial also showed higher reactogenicity

The efficacy advantage came with more common short-term solicited reactions than the standard-dose comparator.

In the peer-reviewed P304 results, reported reactions included:

These figures describe reactogenicity, not vaccine effectiveness. They are useful because they show that the mRNA formulation produced more frequent short-term symptoms than the standard-dose comparator in the trial.

The FDA’s review considered the broader safety database as well. Moderna’s advisory briefing describes an integrated safety dataset spanning more than 71,000 participants aged 50 and older across four Phase 3 studies.

Why the comparator question matters

One of the more technically interesting parts of mFLUSIVA’s regulatory history was the choice of comparator.

The pivotal efficacy trial compared mRNA-1010 with a standard-dose licensed flu vaccine. That is informative for the overall 50+ population, but for adults aged 65 and older, U.S. guidance preferentially recommends high-dose, recombinant or adjuvanted influenza vaccines when available.

That is why the FDA separately examined high-dose-comparator immunogenicity data for the older population rather than simply treating the standard-dose efficacy comparison as the entire evidence package for everyone over 65.

This also limits simplistic claims that mFLUSIVA is now proven superior to every flu vaccine on the U.S. market. The 26.6% efficacy figure is a comparison with the standard-dose vaccine used in P304. Different vaccine technologies, dose levels, seasons and populations require their own evidence.

What is confirmed—and what is not

Several points are now well supported:

• mFLUSIVA is an FDA-approved mRNA seasonal influenza vaccine for adults 50 and older.
• Traditional approval applies to ages 50–64.
• Accelerated approval applies to ages 65 and older and carries a confirmatory-study requirement.
• The pivotal trial showed 26.6% relative efficacy over a licensed standard-dose comparator.
• The trial was large, randomized, active controlled and peer reviewed.
• mRNA manufacturing avoids egg-based virus propagation and its associated egg-adaptive mutation issue.

Other claims should remain qualified.

The P304 result comes from a particular influenza season and comparator. It does not establish a fixed real-world effectiveness advantage that will necessarily repeat every year. It also does not prove that mFLUSIVA outperforms every high-dose, adjuvanted, recombinant or cell-based influenza vaccine.

Commercial availability is separate from regulatory approval. Reuters reported that Moderna does not expect meaningful U.S. commercial impact until the second half of 2027 because the company missed key purchasing cycles for the 2026–2027 season. Availability can therefore lag the regulatory milestone.

Why this approval is technically significant

The more important story is larger than one product.

mRNA vaccine platforms have now moved from pandemic-specific use into a routinely reformulated seasonal vaccine category. Influenza is a demanding test case because strain selection, manufacturing lead times and antigenic mismatch directly affect the value of a production platform.

The FDA approval does not settle whether mRNA will displace egg-based or other flu-vaccine technologies. What it does establish is that an mRNA seasonal influenza vaccine has crossed the full U.S. regulatory threshold for one adult age group and the accelerated-approval threshold for another, backed by a large head-to-head Phase 3 efficacy trial.

For vaccine-platform engineering, that is the key milestone: mRNA is no longer only a rapid-response technology for an emerging pathogen. It is now an approved platform for a seasonal vaccine that must be reformulated and manufactured repeatedly as the target changes.

Sources

• FDA briefing document for mFLUSIVA / mRNA-1010, June 18, 2026
• FDA presentation: Review of Efficacy, Immunogenicity, and Safety of mFLUSIVA, June 18, 2026
• Moderna briefing document submitted to the FDA advisory committee
• New England Journal of Medicine: Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
• Reuters: U.S. FDA approves first mRNA flu shot from Moderna, August 6, 2026
• Associated Press: New kind of flu shot is on the way as FDA approves Moderna’s mRNA-based vaccine